Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials

PURPOSE: Hematologic toxicities, including neutropenia, thrombocytopenia, and anemia, are major adverse effects of PARP inhibitors (PARPis), but the incidence rate and overall risk has not been systematically studied. Therefore, we conducted a meta-analysis of published clinical trials to investigat...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jian xin, Feng, Li jin, Zhang, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648323/
https://www.ncbi.nlm.nih.gov/pubmed/29075104
http://dx.doi.org/10.2147/DDDT.S147726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648323/
https://www.ncbi.nlm.nih.gov/pubmed/29075104
http://dx.doi.org/10.2147/DDDT.S147726

Ejemplares similares